Hematological Neoplasms
In the case of axicabtagene ciloleucel, the T-cells are engineered to target and eliminate cells that express a protein called CD19, which is found on the surface of B-cells, including the cancerous B-cells in follicular lymphoma.
On December 21, 2023, Kite, a Gilead company, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel), incorporating the pivotal Phase 3 ZUMA-7 study’s overall survival (OS) analysis.
On March 5, 2021, the U.S. Food and Drug Administration (FDA) approved Axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
On September 28, 2022, the European Commission (EC) approved the CD19 CAR-T cell therapy Yescarta (axicabtagene ciloleucel) for a new indication: the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after one line of systemic therapy.
On June 28, 2022, local time, Gilead’s cell therapy company Kite Pharma announced that the European Commission (EC) has approved its CAR-T cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
**Заголовок: Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui** Владимир Борзёнков, 68-летний пациент из Санкт-Петербурга, Россия, недавно завершил ключевой этап терапии CAR-T — реинфузию — в международной больнице Jiahui в Шанхае. Этот важный шаг включает повторное введение Т-клеток, которые были генетически модифицированы для распознавания и атаки определённых раковых Read More
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai** Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and Read More
Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy that received FDA approval in 2017 for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and transformed follicular lymphoma (TFL).
In early April 2024, the U.S. Food and Drug Administration (FDA) approved an updated prescribing information for Yescarta (Axicabtagene Ciloleucel) to include overall survival (OS) data in adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after first-line therapy containing Rituximab Injection and Anthracyclines.
On October 17, 2022, exciting news arrived from the European Commission (EC). Based on data from the ZUMA-7 study, the EC officially approved a new indication for Yescarta® for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who are refractory to or relapse within 12 months after first-line chemoimmunotherapy.